Skip Navigation

Nucleic Acids Research 2006 34(Database Issue):D607-D612; doi:10.1093/nar/gkj082
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (3860K) Freely available
Right arrow Screen PDF (317K) Freely available
Right arrow Supplementary Material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Wang, X.
Right arrow Articles by Chen, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, X.
Right arrow Articles by Chen, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2006, Vol. 34, Database issue D607-D612
© The Author 2006. Published by Oxford University Press. All rights reserved
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions{at}oxfordjournals.org

Article

HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma

Xiaosong Wang1,3, Haitao Zhao4, Qingwen Xu1, Weibo Jin2, Changning Liu2, Huagang Zhang1, Zhibin Huang1, Xinyu Zhang6, Yu Zhang1, Dianqi Xin3, Andrew J. G. Simpson5, Lloyd J. Old5, Yanqun Na3, Yi Zhao2 and Weifeng Chen1,*

1Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center Beijing 100083, China 2Bioinformatics Research Group, Key Laboratory of Intelligent Information Processing, Institute of Computing Technology Beijing 100080, China 3Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University Beijing 100034, China 4Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing 100032, China 5Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan–Kettering Cancer Center New York, NY 10021, USA 6Department of Biological Science and Biotechnology, Ministry of Education Key Laboratory of Bioinformatics, Tsinghua University Beijing 100084, China

*To whom correspondence should be addressed. Tel: +86 10 8280 2593; Fax: +86 10 8280 1436; Email: wfchen{at}public.bta.net.cn

Received August 15, 2005. Revised September 20, 2005. Accepted October 11, 2005.

Tumor-associated antigens (TAAs) have been the most actively employed targets in the clinical diagnosis and treatment of human carcinoma, such as PSA in the diagnosis of prostate cancer and NY-ESO-1 in the immunotherapy of melanoma and other cancers. However, identification of TAAs has often been hampered by the complicated and laborsome laboratory procedures. In order to accelerate the process of tumor antigen discovery, and thereby improve diagnosis and treatment of human carcinoma, we have made an effort to establish a publicly available Human Potential Tumor Associated Antigen database (HPtaa) with potential TAAs identified by in silico computing (http://www.hptaa.org). Tumor specificity was chosen as the core of tumor antigen evaluation, together with other relevant clues. Various platforms of gene expression, including microarray, expressed sequence tag and SAGE data, were processed and integrated by several penalty algorithms. A total of 3518 potential TAAs have been included in the database, which is freely available to academic users. As far as we know, this database is the first one addressing human potential TAAs, and the first one integrating various kinds of expression platforms for one purpose.

Correspondence may also be addressed to Yi Zhao. Tel: +86 10 6256 5533, ext. 5717; Fax: +86 10 6256 7724; Email: biozy{at}ict.ac.cn

The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
X.-S. Wang, Z. Zhang, H.-C. Wang, J.-L. Cai, Q.-W. Xu, M.-Q. Li, Y.-C. Chen, X.-P. Qian, T.-J. Lu, L.-Z. Yu, et al.
Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma.
Clin. Cancer Res., August 15, 2006; 12(16): 4851 - 4858.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.